Neos Therapeutics to Review Unsolicited Proposal from PDL BioPharma

Thursday, October 26, 2017 Drug News
Email Print This Page Comment bookmark
Font : A-A+

DALLAS and FORT WORTH, Texas, Oct. 26, 2017 /PRNewswire/ -- Neos Therapeutics, Inc. (Nasdaq:

NEOS), a pharmaceutical company focused on developing, manufacturing and commercializing innovative extended-release (XR) products using its proprietary modified-release drug delivery and orally disintegrating tablet (ODT) technologies, today confirmed
that it has received an unsolicited proposal from PDL BioPharma, Inc. (NASDAQ: PDLI) to acquire all of the outstanding shares of Neos for $10.25 per share in cash.

Consistent with its fiduciary duties and in consultation with its independent legal and financial advisors, the Neos Board of Directors will carefully review and consider the PDL proposal to determine the course of action that it believes is in the best interest of the Company and Neos shareholders.

Neos noted that the proposal received today follows an unsolicited proposal from PDL on June 23, 2017 to acquire the Company for $10.25 per share in cash, which was unanimously rejected by the Neos Board of Directors as not in the best interest of Neos shareholders. 

On July 31, 2017, PDL submitted another unsolicited acquisition proposal at the same price.  At that time, and to facilitate engagement and sharing of information between the companies, Neos entered into a confidentiality agreement with PDL. Following these discussions, PDL again made a proposal to acquire Neos for $10.25 per share in cash despite affirming to Neos that it saw even greater value in the Company as a result of the information shared.

Consistent with its fiduciary duties and in consultation with its independent legal and financial advisors, the Neos Board of Directors carefully reviewed and considered the July PDL proposal.  Following this review, the Neos Board unanimously determined that PDL's proposal substantially undervalued Neos, did not reflect Neos' strategic value and future prospects for continued growth and value creation, and was not in the best interests of the Company or Neos shareholders.

In making the determination to reject the July $10.25 per share proposal, the Neos Board considered, among other things, that the Company is successfully executing its strategy and the Board believes management is well positioned to continue executing on this strategy to drive additional value creation in both the near and long-term.

The Neos Board will respond to the PDL proposal received today in due course.  Neos shareholders do not need to take any action at this time.

Goodwin Procter LLP is serving as legal counsel to Neos, and Jefferies LLC is acting as financial advisor.

About Neos Therapeutics

Neos Therapeutics, Inc. (NASDAQ:NEOS) is a pharmaceutical company focused on developing, manufacturing and commercializing products utilizing its proprietary modified-release drug delivery technology platforms. Adzenys XR-ODT® (amphetamine) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING), Cotempla XR-ODT™ (methylphenidate) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING), and Adzenys-ER™ (amphetamine) extended-release oral suspension (see Full Prescribing Information, including Boxed WARNING), all for the treatment of ADHD, are the first three approved products using the Company's extended-release  technology platform. In addition, Neos manufactures and markets its generic version of the branded product Tussionex®1, an extended-release oral suspension of hydrocodone and chlorpheniramine for the relief of cough and upper respiratory symptoms of a cold (see Full Prescribing Information, including Boxed WARNING). Additional information about Neos is available at www.neostx.com.

1Tussionex® is a registered trademark of the UCB Group of Companies.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events or our future financial or operating performance. In some cases, you can identify forward-looking statements because they contain words such as "may," "will," "should," "expects," "plans," "anticipates," "could," "intends," "target," "projects," "contemplates," "believes," "estimates," "predicts," "potential" or "continue" or the negative of these words or other similar terms or expressions that concern our expectations, strategy, plans or intentions. These forward-looking statements reflect our current views about our expectations, strategy, plans, prospects or intentions, which are based on the information currently available to us and on assumptions we have made. Although we believe that our plans, intentions, expectations, strategies and prospects as reflected in or suggested by those forward-looking statements are reasonable, we can give no assurance that the plans, intentions, expectations or strategies will be attained or achieved. Furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a variety of risks and factors that are beyond our control including, without limitation, our ability to market and sell our product candidates and other risks set forth under the caption "Risk Factors" in our most recently filed Annual Report on Form 10-K as updated by our subsequently filed other SEC filings, including our Quarterly Report(s) on Form 10-Q. We assume no obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.

Contacts:

Media:Barrett Golden and Andrew SquireJoele Frank, Wilkinson Brimmer Katcher(212) 355-4449

Investors:Richard EisenstadtChief Financial OfficerNeos Therapeutics(972) [email protected]

View original content:http://www.prnewswire.com/news-releases/neos-therapeutics-to-review-unsolicited-proposal-from-pdl-biopharma-300544009.html

SOURCE Neos Therapeutics, Inc.



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store